Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06356129 · ClinicalTrials.gov registry record · Phase 3
Study to Compare the Effectiveness and Safety of Golcadomide Plus R-CHOP vs Placebo Plus R-CHOP in Participants With Previously Untreated High-risk Large B-cell Lymphoma
A Phase 3 study of Large B-cell Lymphoma, sponsored by Celgene.
- Active
- Registry status
- Phase 3
- Development phase
- 850
- Enrollment target
- 20
- Study locations
NCT06356129: Active Phase 3 study of Large B-cell Lymphoma, sponsored by Celgene.
NCT06356129 is a Phase 3 study of Large B-cell Lymphoma that is active but no longer recruiting, run by Celgene. The registered enrollment target is 850 participants, above the 129-participant average among 28 other Large B-cell Lymphoma trials with a reported enrollment target (559% higher). The trial reports 20 study locations across 10 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06356129, a Phase 3 study of Large B-cell Lymphoma, is active but no longer recruiting, sponsored by Celgene.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 850 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to compare the effectiveness and safety of golcadomide in combination with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) chemotherapy vs placebo in combination with R-CHOP chemotherapy in participants with previously untreated high-risk large B-cell lymphoma (LBCL).
Conditions Studied
Interventions
- DRUG Cyclophosphamide
- DRUG Placebo
- DRUG Doxorubicin
- DRUG Rituximab
- DRUG Golcadomide
Study Locations (20)
Florida
- Local Institution - 0497 - Fort Myers
- Local Institution - 0287 - Jacksonville
- Local Institution - 0415 - Margate
- Local Institution - 0045 - Miami Beach
- Local Institution - 0012 - Pensacola
- Local Institution - 0502 - St. Petersburg
- Local Institution - 0414 - Tampa
- Local Institution - 0192 - West Palm Beach
- Local Institution - 0485 - Weston
Georgia
- Local Institution - 0515 - Atlanta
- Local Institution - 0303 - Atlanta
Illinois
- Local Institution - 0182 - Chicago
- Local Institution - 0048 - Skokie
Alabama
- Local Institution - 0014 - Mobile
Alaska
- Local Institution - 0477 - Anchorage
Arizona
- Local Institution - 0452 - Phoenix
California
- Local Institution - 0342 - San Francisco
Iowa
- Local Institution - 0461 - Waukee
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 850 participants |
| Start Date | 2024-06-19 |
| Est. Completion | 2029-11-20 |
| Phase | Phase 3 |
What the registry record for NCT06356129 still lists
NCT06356129 is an interventional study that assigns participants to a tested intervention. The registered 850 participants enrollment target is mid-sized for trials with a published cap, above the 129-participant average among 28 other Large B-cell Lymphoma trials with a reported enrollment target (559% higher).
The record links to 1 condition, with Large B-cell Lymphoma appearing as the primary indexed condition, and to 5 interventions - of which Cyclophosphamide is the first listed.
NCT06356129 names 20 study sites across 10 states, led by Florida, Georgia, Illinois.
Frequently Asked Questions
What is clinical trial NCT06356129 about?
NCT06356129 is a clinical study titled "Study to Compare the Effectiveness and Safety of Golcadomide Plus R-CHOP vs Placebo Plus R-CHOP in Participants With Previously Untreated High-risk Large B-cell Lymphoma". The purpose of this study is to compare the effectiveness and safety of golcadomide in combination with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) chemotherapy vs placebo in combination with R-CHOP chemotherapy in participants with previously untreated high-risk l...
What is the current status of trial NCT06356129?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 850 participants. The study started on 2024-06-19. Estimated completion is 2029-11-20.
What conditions does trial NCT06356129 study?
This clinical trial studies the following conditions: Large B-cell Lymphoma.
What interventions are being tested in trial NCT06356129?
The interventions under investigation include: Cyclophosphamide (DRUG), Placebo (DRUG), Doxorubicin (DRUG), Rituximab (DRUG), Golcadomide (DRUG).
Who is sponsoring clinical trial NCT06356129?
This trial is sponsored by Celgene, which has 308 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06356129 being conducted?
This trial has 20 study locations across Alabama, Alaska, Arizona, California, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Large B-cell Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06356129's enrollment target sits among peer trials
850 2nd of 28 the highest of 28 other Large B-cell Lymphoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Large B-cell Lymphoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy
RECRUITING · Phase 3
-
An Open-Label Study Comparing Glofitamab and Polatuzumab Vedotin + Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone Versus Pola-R-CHP in Previously Untreated Patients With Large B-Cell Lymphoma
ACTIVE NOT RECRUITING · Phase 3
-
Study of a Communication Training Intervention for Large B-Cell Lymphoma Providers
RECRUITING · NA
-
A Safety and Efficacy Study Evaluating CTX112 in Subjects With Relapsed or Refractory B-Cell Malignancies
RECRUITING · Phase 1
-
AutologousCD22 Chimeric Antigen Receptor (CAR)T Cells in w/Recurrent/Refractory B Cell Lymphomas
RECRUITING · Phase 1
-
A Phase II Study of Loncastuximab Tesirine as Consolidation Strategy in Patients With LBCL in PR After CAR T-cell Therapy
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03507257 · 850 participants
Longitudinal Early-onset Alzheimer's Disease Study Protocol
- NCT05846841 · 850 participants · NA
Personalized Tobacco Treatment in Primary Care (MOTIVATE)
- NCT05987059 · 850 participants · Phase 2
Involving Communities in Addressing the Maternal Health Crisis: Making an IMPACT
- NCT06289673 · 850 participants · Phase 4
Identification of Necessary Information for Treatment Induction in Newly Diagnosed Acute Lymphoblastic Leukemia/Lymphoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI